Biomakers operates a centralized precision oncology platform that combines large‑scale genomic testing, clinical data aggregation, biobanking, and AI‑driven analytics across 18 Latin American countries. The integrated workflow delivers high‑quality molecular test results and tumor specimen storage, providing clinicians with actionable treatment insights and life‑science partners with diverse, real‑world genomic datasets to accelerate drug and diagnostic development.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ZFFounders
Product
Problem
Oncologic drug and diagnostic development relies on genomic data that underrepresents the genetic diversity of Latin American populations, limiting the relevance of research findings and the effectiveness of precision therapies for patients in the region.
Solution
Biomakers builds a centralized precision oncology ecosystem that integrates large‑scale genomic testing, clinical data aggregation, biobanking, and AI‑driven analytics. By operating a unified network across 18 Latin American countries, the platform generates high‑quality molecular test results and stores tumor specimens, creating a comprehensive data resource that reflects the region’s diverse genetics. The AI‑native analytics layer transforms this data into actionable insights for clinicians, enabling personalized treatment decisions, and for life‑science partners, accelerating the development of new therapeutics and diagnostics. The end‑to‑end solution expands access to precision cancer care for patients while providing innovators with globally relevant datasets.
Target Audience
Primary customers are healthcare providers and oncologists seeking comprehensive molecular testing and decision support, and pharmaceutical or diagnostic companies that require diverse, real‑world genomic data to inform product development.
Features
- Integrated workflow linking genomic sequencing, clinical records, and biobank specimen management in a single platform
- AI‑powered analytics that derive molecular profiles, predictive biomarkers, and treatment recommendations from aggregated data
- Large‑scale biobanking of tumor samples across 18 countries, supporting research and validation studies
- Cloud‑based data infrastructure that ensures secure, compliant sharing of de‑identified patient information with healthcare providers and industry partners
- Scalable network capable of processing nearly 500,000 molecular tests, delivering rapid turnaround for precision oncology workflows